Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

被引：0
|
作者：
Amadori, D.
Gasparini, G.
Ardizzoni, A.
Comella, G.
Saracchini, S.
Barone, C.
Bordonaro, R.
Djazouli, K.
Barbalo, A.
机构：
[1] Ist Sci Romagnolo Studio & Lacura Tumori, Meldola, Forli Cesena, Italy
[2] Azienda Complesso Osped S Filippo Neri, Rome, Italy
[3] AO Univ Parma, Parma, Italy
[4] Fondaz G Pascale, Naples, Italy
[5] AO Santa Maria Angeli, Pordenone, Italy
[6] Policlin Univ A Gemelli, Rome, Italy
[7] Azienda Garibaldi, Catania, Italy
[8] Cephalon Europe, Paris, France
[9] Cephalon Srl, Rome, Italy
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247S / 247S
页数：1
相关论文
共 50 条
  • [31] COMBINATION OF TRASTUZUMAB, OXALIPLATIN AND DOCETAXEL AS FIRST LINE TREATMENT IN HER2-POSITIVE ADVANCED BREAST CANCER PATIENTS: PRELIMINARY RESULTS OF A PHASE II TRIAL (HOT TRIAL)
    Amoroso, Domenico
    Donati, Sara
    Rondini, Marianna
    Valsuani, Chiara
    Siclari, Olimpia
    Puccetti, Cheti
    Tartarelli, Gianna
    Puccinelli, Paolo
    Giannessi, Piergiorgio
    Falcone, Alfredo
    Camerini, Andrea
    ANNALS OF ONCOLOGY, 2009, 20
  • [32] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [33] Phase II study of neoadjuvant trastuzumab Plus docetaxel for locally advanced and metastatic breast cancer that overexpresses HER2/neu: a preliminary report.
    Van Pelt, AE
    Elledge, RM
    Allred, DC
    Mohsin, SK
    Gutierrez, MC
    Chang, JC
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S114 - S114
  • [34] A comparison of the efficacy of trastuzumab and chemotherapy combination as a first or second-line treatment regimen in metastatic, HER-2/neu overexpressed breast cancer patients
    Bauer-Kosinska, Barbara
    Lemanska, Izabella
    Glogowska, Iwona
    Pienkowski, Tadeusz
    ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
  • [35] DOCETAXEL IN COMBINATION WITH NON PEGYLATED LIPOSOMEEN CAPSULATED DOXORUBICIN (MYOCET) FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC) PATIENTS: A PHASE II CLINICAL STUDY
    Cutuli, Irene
    Orizzonte, Giovanna
    Condemi, Giovanni
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer
    Leung, Henry W. C.
    Chan, Agnes L. F.
    Muo, Chih-Hsin
    Leung, John Hang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (02) : 207 - 213
  • [37] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [38] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [39] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
  • [40] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
12345